Schaefer Inga-Marie, Fletcher Christopher Dm, Hornick Jason L
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Mod Pathol. 2016 Jan;29(1):4-13. doi: 10.1038/modpathol.2015.134. Epub 2015 Nov 20.
The diagnosis of malignant peripheral nerve sheath tumor is challenging, particularly in the sporadic setting. Inactivation of the polycomb repressive complex 2 (PRC2), resulting from inactivating mutations of its constituents SUZ12 or EED1, has recently been identified in 70-90% of malignant peripheral nerve sheath tumors. Homozygous PRC2 inactivation results in loss of histone H3K27 trimethylation (H3K27me3). PRC2 inactivation promotes tumor progression and may render patients sensitive to epigenetic-based targeted therapies. H3K27me3 loss has not yet been validated as a diagnostic marker. We evaluated immunohistochemistry for H3K27me3 in 100 malignant peripheral nerve sheath tumors (70 sporadic, 10 neurofibromatosis type 1-associated, 10 radiation-associated, 10 epithelioid) and 200 other spindle cell neoplasms representing potential mimics (20 each monophasic synovial sarcoma, leiomyosarcoma, dedifferentiated liposarcoma, malignant solitary fibrous tumor, low-grade fibromyxoid sarcoma, cellular schwannoma, spindle cell melanoma, unclassified postradiation sarcoma; 10 each atypical neurofibroma, spindle cell rhabdomyosarcoma, gastrointestinal stromal tumor, fibrosarcomatous dermatofibrosarcoma protuberans). In total, 51 (51%) malignant peripheral nerve sheath tumors, including 34 (49%) sporadic, 7 (70%) neurofibromatosis type 1-associated, and 10 (100%) radiation-associated, but no epithelioid malignant peripheral nerve sheath tumors, were negative for H3K27me3. An additional 6 (6%) tumors showed heterogeneous H3K27me3 expression. Among the 90 sporadic, neurofibromatosis type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors, complete H3K27me3 loss was observed in 29% of low-grade, 59% of intermediate-grade, and 83% of high-grade tumors (low vs intermediate/high grade, P=0.0003). Among other tumor types, 4 (20%) unclassified postradiation sarcomas were negative for H3K27me3, whereas all other neoplasms were positive. Loss of H3K27me3 is highly specific for malignant peripheral nerve sheath tumor (although only modestly more sensitive than S-100 protein and SOX10) and may be a useful diagnostic marker. Our findings suggest that PRC2 inactivation in malignant peripheral nerve sheath tumor may occur during progression to higher grades.
恶性外周神经鞘瘤的诊断具有挑战性,尤其是在散发性病例中。最近在70%-90%的恶性外周神经鞘瘤中发现了由其组成成分SUZ12或EED1的失活突变导致的多梳抑制复合体2(PRC2)失活。PRC2纯合失活导致组蛋白H3K27三甲基化(H3K27me3)缺失。PRC2失活促进肿瘤进展,并可能使患者对基于表观遗传学的靶向治疗敏感。H3K27me3缺失尚未被证实为一种诊断标志物。我们评估了100例恶性外周神经鞘瘤(70例散发性、10例1型神经纤维瘤病相关、10例放疗相关、10例上皮样)和200例其他可能具有相似表现的梭形细胞肿瘤(各20例单相滑膜肉瘤、平滑肌肉瘤、去分化脂肪肉瘤、恶性孤立性纤维性肿瘤、低度纤维黏液样肉瘤、细胞性神经鞘瘤、梭形细胞黑色素瘤、未分类的放疗后肉瘤;各10例非典型神经纤维瘤、梭形细胞横纹肌肉瘤、胃肠道间质瘤、纤维肉瘤样隆突性皮肤纤维肉瘤)中H3K27me3的免疫组化情况。总共51例(51%)恶性外周神经鞘瘤H3K27me3呈阴性,包括34例(49%)散发性、7例(70%)1型神经纤维瘤病相关和10例(100%)放疗相关的,但上皮样恶性外周神经鞘瘤均未出现H3K27me3阴性。另外6例(6%)肿瘤显示H3K27me3表达异质性。在90例散发性、1型神经纤维瘤病相关和放疗相关的恶性外周神经鞘瘤中,29%的低级别、59%的中级别和83%的高级别肿瘤观察到完全性H3K27me3缺失(低级别与中/高级别相比,P=0.0003)。在其他肿瘤类型中,4例(20%)未分类的放疗后肉瘤H3K27me3呈阴性,而所有其他肿瘤均为阳性。H3K27me3缺失对恶性外周神经鞘瘤具有高度特异性(尽管仅比S-100蛋白和SOX10略敏感),可能是一种有用的诊断标志物。我们的研究结果表明,恶性外周神经鞘瘤中的PRC2失活可能发生在向更高级别进展的过程中。